Search

Displaying results 5711 - 5720 of 10000 in total
  1. Drug

    Trichosporon cutaneum

    go.drugbank.com/drugs/DB10974
    Approved

    Trichosporon cutaneum allergenic extract is used in allergenic testing.

  2. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

  3. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

  4. Drug

    Milataxel

    go.drugbank.com/drugs/DB12334
    Investigational

    Milataxel has been used in trials studying the treatment of Mesothelioma.

  5. Drug

    Rhodotorula rubra

    go.drugbank.com/drugs/DB10442
    Approved

    Rhodotorula rubra is a fungus which can provoke allergic reactions. Rhodotorula rubra is used in allergenic testing.

  6. Drug

    Rhodotorula mucilaginosa

    go.drugbank.com/drugs/DB10701
    Approved

    Rhodotorula mucilaginosa is a fungus which can provoke allergic reactions. Rhodotorula mucilaginosa is used in allergenic testing.

  7. Drug

    Candida tropicalis

    go.drugbank.com/drugs/DB10807
    Approved

    Candida tropicalis is a fungus which can provoke allergic reactions. Candida tropicalis is used in allergenic testing.

  8. Drug

    Senicapoc

    go.drugbank.com/drugs/DB06280
    Investigational

    Senicapoc (ICA-17043) is a novel Gardos channel blocker.[A259068] It is being investigated for the treatment of sickle cell disease.

  9. Drug

    Bectumomab

    go.drugbank.com/drugs/DB04962
    Experimental

    Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

  10. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.